Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance

Lithium Americas CorpTrade
Relay Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Relay Therapeutics Inc. Common Stock — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Relay Therapeutics Inc. Common Stock trades at $17.88 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is far larger — about 4.5× Lithium Americas Corp's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.

LACRLAY
Market Cap
$850.38M$3.82B
Volume
8,804,6374,332,079
Sector
Basic MaterialsHealth
52-Week High
$10.05$20.75
52-Week Low
$2.36$6.03
Typical Hold Time
27 Days0 Days
Enterprise Value
$1.19B$2.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.

LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.

Relay Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LAC
25% Buy75% Sell
Avg holding period · 27 Days
RLAY
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC →

About Relay Therapeutics Inc. Common Stock

Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.

Read more on RLAY →